Cat. No. | Product name | CAS No. |
DC66773 |
Ficlatuzumab
Featured
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion. |
1174900-84-5 |
DC66774 | Genentech patent anti-HGFA Featured | |
DC66775 |
Amivantamab
Featured
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells. |
2171511-58-1 |
DC66776 |
Onartuzumab
Featured
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. |
1133766-06-9 |
DC66777 |
Emibetuzumab
Featured
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. |
1365287-97-3 |
DC66778 |
Telisotuzumab
Featured
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity. |
1781223-80-0 |
DC66779 | SAIT301 Featured | |
DC66780 | Korea RIBB patent anti-cMet Featured | |
DC66781 | Metheresis patent anti-Met Featured | |
DC66782 | Derlotuximab Featured | |
DC66783 | Immunomedics patent anti-Histone H2B Featured | |
DC66784 | Immunomedics patent anti-Histone H3 Featured | |
DC66785 | Immunomedics patent anti-Histone H4 Featured | |
DC66786 | IMMU-114 Featured | |
DC66787 |
Galegenimab
Featured
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research. |
2403683-24-7 |
DC66788 |
Bersanlimab
Featured
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. |
1987854-08-9 |
DC66789 | Forerunner patent anti-ICAM-3 Featured | |
DC66790 |
Vopratelimab
Featured
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response. |
2039148-04-2 |
DC66791 | MEDI-570 Featured | |
DC66792 |
Alomfilimab
Featured
Alomfilimab(KY-1044; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response. |
2489390-15-8 |
DC66793 |
Feladilimab
Featured
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer. |
2252518-85-5 |
DC66794 | LIMR patent anti-IDO2 Featured |